首页> 外文期刊>Hospital pediatrics. >Outcomes for Pediatric Asthmatic Inpatients After Implementation of an Emergency Department Dexamethasone Treatment Protocol.
【24h】

Outcomes for Pediatric Asthmatic Inpatients After Implementation of an Emergency Department Dexamethasone Treatment Protocol.

机译:在实施急诊科对地塞米松治疗方案后的儿科哮喘住院患者的结果。

获取原文
获取原文并翻译 | 示例
           

摘要

Evidence supports using dexamethasone for mild-to-moderate asthma exacerbations in the emergency department, but the effectiveness of dexamethasone versus prednisone for asthmatic patients who are hospitalized is unclear. Our aim was to compare outcomes for inpatients before and after our emergency department's adoption of dexamethasone for the treatment of acute asthma exacerbations. In this single-center retrospective cohort study, we employed interrupted time series analyses to control for secular trends while evaluating our outcomes of length of stay, total inflation-adjusted hospital charges, and ICU transfer rates for patients admitted with asthma. Data were analyzed over 36 months (January 2014-April 2017) and included 1015 subjects (606 in the preprotocol change [pre-PC] group and 409 in the postprotocol change [post-PC] group). In the pre-PC group, prednisone only was used in 96% of subjects. In the post-PC group, prednisone only was used in 7% of subjects, dexamethasone in 65% of subjects, and a combination of the 2 steroids in 28% of subjects. Controlling for other variables in the interrupted time series model, we found no significant immediate differences between the pre-PC and post-PC periods for the outcomes of length of stay ( P = .68), total charges ( P = .66), and ICU transfers ( P = .98). The rate of ICU transfers was stable pre-PC and increased by 10% (95% confidence interval: 2%-19%) per month (odds ratio = 1.10; 95% confidence interval: 1.02-1.19; P = .02) in the post-PC period. After dexamethasone replaced prednisone as the most commonly prescribed steroid type for inpatients with asthma at our institution, we found no immediate changes in outcomes for asthmatic patients who were hospitalized but an upward trend in ICU transfers.
机译:证据支持使用地塞米松进行急诊部中的温和至中等哮喘加剧,但地塞米松对住院治疗的哮喘患者的泼尼松的有效性尚不清楚。我们的目的是在急诊部门通过地塞米松之前和之后比较住院患者的结果,以治疗急性哮喘加剧。在这项单一中心回顾性队列研究中,我们采用中断的时间序列分析来控制世俗趋势,同时评估我们的住院时间,总通货膨胀调整后的医院费用和ICU转移率为哮喘患者。数据分析了36个月(2017年1月至2017年4月),并包含1015个科目(606人在预称的改变[Pre-PC]组和409中,在后保护改变[POST-PC]组)。在PR PC组中,泼尼松仅用于96%的受试者。在PC PC组中,泼尼松仅用于7%的受试者,以65%的受试者的地塞米松,以及28%受试者的2种类固醇组合。控制中断时间序列模型中的其他变量,我们发现在PC和PC后期之间没有显着的直接差异,以便保持时间长度(P = .68),总费用(P = .66),和ICU转移(p = .98)。 ICU转移的速率稳定PRP预科,每月增加10%(95%置信区间:2%-19%)(差价率= 1.10; 95%置信区间:1.02-1.19; p = .02)后PC期。在地塞米松替代泼尼松作为在我们所在机构的哮喘中最常见的类固醇类型,我们发现没有住院的哮喘患者的结果,但ICU转移的上升趋势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号